Multivalent Shigella ETEC Vaccine Broadening Pathogen Coverage

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current vaccines lack broad coverage against Shigella and Enterotoxigenic Escherichia coli (ETEC) pathogens, which cause significant diarrheal diseases, particularly in developing countries, and do not effectively protect against all serotypes and colonization factors.

Innovation Solution

A multivalent vaccine composition comprising live attenuated Shigella strains, including serotypes 1b and 7a, and ETEC surface antigen CS14, engineered to express various ETEC antigens, providing enhanced protection by including multiple colonization factor antigens and serotypes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If a single-valent Shigella vaccine is used, then the vaccine composition is simple, but the coverage against different Shigella serotypes and ETEC colonization factors is limited

Engineering Contradiction:

Improvecoverage against Shigella serotypes and ETEC colonization factorsVSAvoidvaccine composition complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent combines multiple Shigella serotypes (2a, 3a, 6, and 1b) and ETEC colonization factor antigens (CFA/I, CS1, CS2, CS3, CS5, CS6, and CS14) into a single multivalent vaccine composition. This merging approach allows the vaccine to provide broad coverage against diverse Shigella and ETEC strains while maintaining a unified formulation that can be administered as a single dose.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The vaccine is designed with universal applicability against multiple pathogens and serotypes. By incorporating antigens from four Shigella serotypes and seven ETEC colonization factors, the single vaccine composition serves multiple protective functions, covering both Shigella dysentery and ETEC diarrhea across different geographic regions and populations.

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If multiple Shigella serotypes and ETEC antigens are included in the vaccine, then the coverage and protection breadth are enhanced, but the vaccine formulation and production become more complex

Engineering Contradiction:

Improveprotection effectiveness against diverse pathogensVSAvoidvaccine formulation and production

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The vaccine development process is segmented into distinct phases: selecting representative Shigella serotypes based on epidemiological data, identifying predominant ETEC colonization factors, formulating the multivalent composition, and conducting targeted clinical trials. This segmentation allows each component to be optimized independently while maintaining overall manufacturability.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The vaccine formulation utilizes parameter optimization by adjusting the relative proportions of different Shigella serotypes and ETEC antigens based on their epidemiological prevalence. The composition is tailored to reflect the actual distribution of pathogens in target populations, ensuring maximum protection effectiveness while maintaining production efficiency.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS11471520B2Enhanced <i>Shigella</i>-enterotoxigenic <i>E. coli </i>multi-valent vaccine

Publication Date: 2022.10.18 UNIV OF MARYLAND

AI summary

The invention relates to a multivalent Shigella/Enterotoxigenic Escherichia coli vaccine for use in prophylaxis and treatment of diarrheal disease. The Shigella-ETEC vaccine provides increased coverage of a broader range of ETEC and Shigella isolates than prior vaccines, and includes CS14 antigens and serotypes (S. flexneri 7a, or S. flexneri 1b).